CA9 antibody

Catalog No. ABIN6654742

The Rabbit Monoclonal anti-CA9 antibody has been validated for IHC (p). It is suitable to detect CA9 in samples from Human.

Quick Overview for CA9 antibody (ABIN6654742)

Target: CA9 (Carbonic Anhydrase IX (CA9))

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This CA9 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: CA9-2993R

Product Details anti-CA9 Antibody

Purification: Purified

Purity: Protein A affinity chromatography

Immunogen: Recombinant human protein was used as the immunogen for this recombinant Carbonic Anhydrase 9 antibody.

Isotype: IgG kappa

Application Details

Application Notes: The optimal dilution of the recombinant Carbonic Anhydrase 9 antibody for each application should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)

Restrictions: For Research Use only

Handling

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant Carbonic Anhydrase 9 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for CA9

Target: CA9 (Carbonic Anhydrase IX (CA9))

Alternative Name: CA9 / Carbonic Anhydrase IX

Background: Recognizes a glycoprotein of ~200 kDa, identified as carbonic anhydrase IX (CAIX/gp200). Its epitope resides in the carbohydrate domain of gp200. It shows no significant cross-reactivity with other carbohydrate determinants, such as the Lewis blood group antigens, epithelial membrane antigen, HMFG, and AB blood group antigens. In normal kidney, gp200 is localized along the brush border of the pars convoluta and pars recta segments of the proximal tubule, as well as focally along the luminal surface of Bowman's capsule adjoining the outgoing proximal tubule. Reportedly, gp200 is expressed by 93 % of primary and 84 % of metastatic renal cell carcinomas. This MAb may be useful in the investigations of carcinomas of proximal nephrogenic differentiation especially those showing tubular differentiation.